Condition
Autoimmune Lymphoproliferative Syndrome
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting2
Withdrawn1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06730126Phase 2RecruitingPrimary
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
NCT01821781Phase 2Active Not Recruiting
Immune Disorder HSCT Protocol
NCT04902807RecruitingPrimary
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
NCT01672918WithdrawnPrimary
Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
Showing all 4 trials